Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome

Journal of General Virology

Volumn 96, Issue 8, 2015, Pages 2252-2261

  Liu, Xing ^a   Hao, Ruidong ^a   Chen, Shuliang ^a   Guo, Deyin ^a   Chen, Yu ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CRISPR ASSOCIATED PROTEIN; GENOMIC DNA; GUIDE RNA; VIRUS DNA; VIRUS RNA;

ANIMAL TISSUE; ARTICLE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS CAS9 SYSTEM; CONTROLLED STUDY; CRISPR CAS SYSTEM; DNA END JOINING REPAIR; DNA SEQUENCE; DNA TEMPLATE; GENE AMPLIFICATION; GENE CONSTRUCT; GENE TARGETING; HEPATITIS B VIRUS; HEPATITIS B VIRUS GENOTYPE D; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; RNA CLEAVAGE; SEQUENCE ALIGNMENT; VIRAL CLEARANCE; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION; ANIMAL; BAGG ALBINO MOUSE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; GENETICS; HEPATITIS B; MALE; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; PROCEDURES; VIROLOGY;

HEPATITIS B VIRUS;

ANIMALS; BASE SEQUENCE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; CONSERVED SEQUENCE; CRISPR-CAS SYSTEMS; GENE TARGETING; GENOME, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; VIRUS REPLICATION;

EID: 84937614537     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.000159     Document Type: Article

References (31)

1. Ayoub, W. S. & Keeffe, E. B. (2011). Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther 34, 1145-1158
2. Bloom, K., Ely, A., Mussolino, C., Cathomen, T. & Arbuthnot, P. (2013). Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. Mol Ther 21, 1889-1897.
3. Cao, L., Wu, C., Shi, H., Gong, Z., Zhang, E., Wang, H., Zhao, K., Liu, S., Li, S. & other authors (2014). Coexistence of hepatitis B virus quasispecies enhances viral replication and the ability to induce host antibody and cellular immune responses. J Virol 88, 8656-8666
4. Chan, H. L. (2011). Significance of hepatitis B virus genotypes and mutations in the development of hepatocellular carcinoma in Asia. J Gastroenterol Hepatol 26, 8-12.
5. Chudy, M., Hanschmann, K. M., Kress, J., Nick, S., Campos, R., Wend, U., Gerlich, W. & Nubling, C. M. (2012). First WHO International Reference Panel containing hepatitis B virus genotypes A-G for assays of the viral DNA. J Clin Virol 55, 303-309.
6. Cradick, T. J., Fine, E. J., Antico, C. J. & Bao, G. (2013). CRISPR/Cas9 systems targeting b-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res 41, 9584-9592.
7. Ebina, H., Misawa, N., Kanemura, Y. & Koyanagi, Y. (2013). Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep 3, 2510
8. Gaj, T., Gersbach, C. A. & Barbas, C. F. (2013). ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 31, 397-405.
9. Hao, R., He, J., Liu, X., Gao, G., Liu, D., Cui, L., Yu, G., Yu, W., Chen, Y. & other authors (2015). Inhibition of hepatitis B virus gene expression and replication by hepatocyte nuclear factor 6. J Virol 89, 4345-4355
10. Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X. & other authors (2013). DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 31, 827-832.
11. Hsu, P. D., Lander, E. S. & Zhang, F. (2014). Development and applications of CRISPR-Cas9 for genome engineering. Cell 157, 1262-1278.
12. Huang, L. R., Wu, H. L., Chen, P. J. & Chen, D. S. (2006). An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci U S A 103, 17862-17867
13. Jablonowski, H. (2003). IFN-alpha: therapeutic options in HIV and HIV/HCV, HIV/HBV dual infection. Infection 31, 131-133.
14. Januszkiewicz-Lewandowska, D., Rucka, A., Kowala-Piaskowska, A., Bereszynska, I., Mozer-Lisewska, I., Zajac-Spychala, O., Wysocki, J. & Nowak, J. (2014). Mutations in Pol gene of hepatitis B virus in patients with chronic hepatitis B before and after therapy with nucleoside/ nucleotide analogues. Acta Virol 58, 185-189.
15. Joung, J. K. & Sander, J. D. (2013). TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol 14, 49-55.
16. Kennedy, E. M., Bassit, L. C., Mueller, H., Kornepati, A. V., Bogerd, H. P., Nie, T., Chatterjee, P., Javanbakht, H., Schinazi, R. F. & Cullen, B. R. (2014). Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/ Cas RNA-guided DNA endonuclease. Virology 476, 196-205.
17. Li, F., Zhang, D., Li, Y., Jiang, D., Luo, S., Du, N., Chen, W., Deng, L. & Zeng, C. (2015). Whole genome characterization of hepatitis B virus quasispecies with massively parallel pyrosequencing. Clin Microbiol 21, 280-287.
18. Lin, S. R., Yang, H. C., Kuo, Y. T., Liu, C. J., Yang, T. Y., Sung, K. C., Lin, Y. Y., Wang, H. Y., Wang, C. C. & other authors (2014). The CRISPR/ Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo. Mol Ther Nucleic Acids 3, e186.
19. Liu, D., Wu, A., Cui, L., Hao, R., Wang, Y., He, J. & Guo, D. (2014a). Hepatitis B virus polymerase suppresses NF-kB signaling by inhibiting the activity of IKKs via interaction with Hsp90b. PLoS One 9, e91658.
20. Liu, J., Kosinska, A., Lu, M. & Roggendorf, M. (2014b). New therapeutic vaccination strategies for the treatment of chronic hepatitis B. Virol Sin 29, 10-16
21. Mani, M., Kandavelou, K., Dy, F. J., Durai, S. & Chandrasegaran, S. (2005). Design, engineering, and characterization of zinc finger nucleases. Biochem Biophys Res Commun 335, 447-457.
22. Perz, J. F., Armstrong, G. L., Farrington, L. A., Hutin, Y. J. & Bell, B. P. (2006). The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45, 529-538.
23. Schadler, S. & Hildt, E. (2009). HBV life cycle: entry and morphogenesis. Viruses 1, 185-209.
24. Seeger, C. & Sohn, J. A. (2014). Targeting hepatitis B virus with CRISPR/Cas9. Mol Ther Nucleic Acids 3, e216.
25. Tian, Y., Chen, W. L. & Ou, J. H. (2011). Effects of interferon-a/b on HBV replication determined by viral load. PLoS Pathog 7, e1002159
26. Weber, N. D., Stone, D., Sedlak, R. H., De Silva Feelixge, H. S., Roychoudhury, P., Schiffer, J. T., Aubert, M. & Jerome, K. R. (2014). AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication. PLoS One 9, e97579.
27. Werle-Lapostolle, B., Bowden, S., Locarnini, S., Wursthorn, K., Petersen, J., Lau, G., Trepo, C., Marcellin, P., Goodman, Z. & Delaney, W. E. IV (2004). Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126, 1750-1758.
28. Wilson, A. C. & Patient, R. K. (1991). Evaluation of extrachromosomal gene copy number of transiently transfected cell lines. Methods Mol Biol 7, 397-404.
29. Xie, Y. H., Hong, R., Liu, W., Liu, J. & Zhai, J. W. (2010). Development of novel therapeutics for chronic hepatitis B. Virol Sin 25, 294-300
30. Yuen, K. S., Chan, C. P., Wong, N. H., Ho, C. H., Ho, T. H., Lei, T., Deng, W., Tsao, S. W., Chen, H. & other authors (2015). CRISPR/Cas9-mediated genome editing of Epstein-Barr virus in human cells. J Gen Virol 96, 626-636.
31. Zhen, S., Hua, L., Liu, Y. H., Gao, L. C., Fu, J., Wan, D. Y., Dong, L. H., Song, H. F. & Gao, X. (2015). Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus. Gene Ther 22, 404-412